Phase II study of the addition of rituximab to dmCODOX-M/IVAC therapy for AIDS-related burkitt lymphoma
Phase 2
- Conditions
- AIDS-related burkitt lymphoma
- Registration Number
- JPRN-UMIN000011661
- Lead Sponsor
- ational Hospital Organization Nagoya Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnant or possible pregnant women 2. Other active malignancies except for Kaposi sarcoma 3. Severe complication Uncontrollable angina pectoris, myocardial infarction, or heart failure Uncontrollable active infection Uncontrollable diabetes Interstitial pneumonia or pulmonary fibrosis by chest-Xay Uncontrollable opportunistic disease of central nervous system Uncontrollable pleural effusion, ascites or fluid retention in third space Severe psychosis 4. Judged for inappropriate with other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Two-year progression-free survival
- Secondary Outcome Measures
Name Time Method Two-year overall survival, complete response rate, overall response rate, adversed effect, incidence of opportunistic disease, treatment-related mortality